Biochemotherapy with thymosin αl, interleukin-2 and dacarbazine in patients with metastatic melanoma: Clinical and immunological effects

Annals of Oncology

Volumn 5, Issue 8, 1994, Pages 741-746

  Lopez, M ^a,b   Carpano, S ^d   Cavaliere, R ^d   Di Lauro, L ^d   Ameglio, F ^a,b   Vitelli, G ^d   Frasca, A M ^d   Vici, P ^d   Pignatti, F ^d   Rosselli, M ^d   Rasi, G ^a,c   Garaci, E ^a,c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d NONE

Author keywords

Advanced melanoma; Biochemotherapy; DTIC; Interleukin 2; Thymosin l

Indexed keywords

DACARBAZINE; DOPAMINE; INDOMETACIN; INTERLEUKIN 2; ONDANSETRON; PARACETAMOL; RECOMBINANT INTERLEUKIN 2; THYMOSIN ALPHA1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTIGENS, CD4; ANTIGENS, CD8; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; HUMAN; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGE; NEOPLASM METASTASIS; REMISSION INDUCTION; SKIN NEOPLASMS; THYMOSIN;

EID: 0028168087     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a058979     Document Type: Article

References (23)

1. A.N. Houghton S. Legha D.F. Bajorin Chemotherapy for metastatic melanoma. In Balch CM, Houghton AN, Sober AJ Cutaneous Melanoma 1992 JB Lippincott Philadelphia 498 508
2. D.R. Parkinson A.N. Houghton P. Hersey Biologic therapy for melanoma Cutaneous Melanoma 1992 JB Lippincott Philadelphia 522 541
3. W.H. West K.W. Tauer J.R. Yannelli Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer N Engl J Med 316 1987 898 905
4. K. Kashmanian Oates A.L. Goldstein Thymosin Biologic Therapy of Cancer. JB Lippincott Philadelphia 1991 705 718
5. A. Mastino C. Favalli S. Grelli Combination therapy of thymosin al potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice Int J Cancer 50 1992 493 499
6. A.B. Miller B. Hoogstraten H. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
7. P.M. LoRusso L. Polin S.L. Auckerman Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems Cancer Res 50 1990 4876 4882
8. P.A. Demchak J.W. Mier N.J. Robert A phase II pilot trial of interleukin-2 and high-dose cisplatin in patient with metastatic melanoma J Clin Oncol 10 1991 147 151
9. M.S. Mitchell Combining chemotherapy with biological response modifiers in treatment of cancer J Natl Cancer Inst 80 1988 1445 1450
10. E. Shiloni P. Pouillart J. Janssens Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma A pilot multicentre phase I-II study. Eur J Cancer Clin Oncol 2 1989 45 49
11. L.E. Flaherty B.G. Redman G.G. Chabot A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma Cancer 65 1990 2471 2477
12. N.E. Papadopoulos J.G. Howard J.L. Murray Phase D DTIC and interleukin-2 trial for metastatic malignant melanoma Proc Am Soc Clin Oncol 9 1990 277
13. R.O. Dillman R.K. Oldham N.M. Barth Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: A National Biotherapy Study Group trial J Natl Cancer Inst 82 1990 1345 1349
14. G. Stoter S. Aamdal S. Rodenhuis Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: A multicenter phase II study J Clin Oncol 9 1991 1687 1691
15. L.E. Flaherty P.Y. Liu W.S. Fletcher Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: Phase II Southwest Oncology Group trial J Natl Cancer Inst 84 1992 893 894
16. D. Thomson M. Adena G.R.C. McLeod Interferon α-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi-institutional australian randomised trial QMP8704 Proc Am Soc Clin Oncol 11 1992 343
17. J.M. Richards N. Mehta K. Ramming Sequential chemo-immunotherapy in the treatment of metastatic melanoma J Clin Oncol 10 1992 1338 1343
18. S.C. Lattanzi T. Tosteson L.H. Maurer Dacarbazine, cisplatin, and carmustine ± tamoxifen, in the treatment of patient with metastatic melanoma: Results of -year follow-up Proc Am Soc Clin Oncol 12 1993 390
19. J. Atzpodien A. Körfer C.R. Franks Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies Lancet 335 1990 1509 1512
20. E. Lopez Hänninen A. Körfer M. Hadam Biological monitoring of low-dose interleukin-2 in humans: Soluble interleukin-2 receptors, cytokines and cell surface phenotypes Cancer Res 50 1991 6312 6316
21. R. Isacson E. Kedar V. Barak Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: Evaluation of hematologic and immunologic parameters and correlation with clinical response Immunol Lett 33 1992 127 134
22. B.G. Redman L. Flaherty T.H. Chou Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: Immunological effects of therapy J Immunol 10 1991 147 151
23. M. Papanastasiou C.N. Baxevanis M. Papamichail Promotion of murine antitumor activity by prothymosin α treatment: I Induction of tumoricidal peritoneal cells producing high levels of tumor necrosis factor α. Cancer Immunol Immunother 35 1992 145 150